TMED2 was significantly upregulated in a wide range of cancers, including ACC, BLCA, BRCA, CESC, CHOL, COAD, DLBC, ESCA, GBM, HNSC, KICH, KIRC, KIRP, LGG, LIHC, LUAD, LUSC, OV, PAAD, PRAD, READ, SARC, SKCM, STAD, TGCT, THYM, UCEC, and UCS, while only LAML exhibited downregulated TMED2 expression (Figure 1A). Here, TMED2 is linked to cancer.